Breaking AI & Tech News Analyzed

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Cooking Gas Crisis in AsiaIn the ramshackle lanes of a south Delhi slum, Afshana Khatoon crouched wearily on her haunches and began lighting a small pile of firewood. She had just returned from six hours spent trudging through the urban forests and dry parks of India's capital looking for kindling to turn into a makeshift stove. As the unforgiving summer heat soared above 40C, she had walked for miles, piling the sticks and fallen branches into a bundle on her head while sweat ran down her face.Just a few weeks ago, the 35-year-old had been preparing meals for her four children on a small gas stove with little fuss. But as the crisis in the Middle East has choked India's vital supplies of imported liquefied petroleum gas (LPG) – used by more than 60% of the country's population for cooking – refills have been scarce and prices have risen far beyond what is widely affordable.Return to Traditional FuelsKhatoon, like growing numbers of people in India and more widely across Asia, has been forced to cook with crude, dirty fuels such as firewood and coal in order to survive. "It already feels like hell," she said, as she bustled about, filling a pot with water. "I'm not eating properly, and I have to work much more than before. My whole day now is about collecting firewood and cooking."The return to fuels such as firewood and coal is not only deepening the economic strain of the war on ordinary civilians in countries across Asia, but raising concerns about public health, air pollution and the fragility of the energy transition.Supply Chain Disruption and Price SurgeIndia imports about 60% of its LPG needs, of which about 90% usually comes through the strait of Hormuz, the critical shipping route still blockaded amid the ongoing conflict between Iran and the US. Official data shows India's LPG consumption fell by 2.2m tonnes in April, the sharpest decline in years.As the war has dragged on, cooking gas prices in informal markets have surged. In Khatoon's dimly lit shanty, her 5kg gas canister sat empty and forlorn in the corner. She said LPG had become prohibitively expensive for her family, rising to more than four times what she used to pay. "My husband earns 400 to 500 rupees a day. We can't spend 1,000 rupees just on gas for a week," she said.While the Indian government insists there is no shortage, in a speech this week the prime minister, Narendra Modi, called on people to adopt austerity measures including limiting their use of fuel and petrol. According to the defence minister, India has petroleum gas reserves to last just 45 days.Health and Environmental ConsequencesOnce Khatoon's fire stove is lit, thick smoke rises from the flames. It stings the eyes and throat but she has no option but to breathe it in as she cooks. She put her head in her hands, admitting she felt utterly exhausted. "We just want to cook as quickly as possible," she said.The return to biomass is raising alarms about air quality in cities across the region. Solid fuels such as wood and charcoal come with a range of health and environmental risks. They emit a dangerous set of pollutants that have been linked to respiratory problems, such as chronic obstructive pulmonary disease and lung cancer, strokes and heart disease.The combined effects of ambient air pollution and household air pollution are associated with 6.7 million premature deaths annually, according to the World Health Organization. Women and children, widely responsible for household chores such as cooking or collecting firewood, are the most vulnerable.Reversal of Environmental ProgressDelhi already ranks among the world's most polluted cities, and years of policy have focused on promoting cleaner fuels such as LPG and compressed natural gas to reduce emissions.Environmental activists fear years of progress toward widespread use of cleaner fuels is being reversed as the war in the Middle East drags on. With shortages deepening, authorities in Delhi have temporarily relaxed restrictions on the use of coal and firewood."When prices rise, it's the poorest who are forced to switch back to biomass," said Harjeet Singh, a climate activist and the founding director of the Satat Sampada Climate Foundation. "Biomass burning is a major source of fine particulate pollution."Future OutlookAs the conflict in the Middle East continues to disrupt global energy supplies, the health implications of reverting to traditional cooking methods across Asia are likely to worsen. Without immediate intervention to either increase LPG supplies or provide affordable alternatives, public health crises in major urban centers could escalate, potentially reversing years of progress in air quality improvement.The situation highlights the vulnerability of energy-dependent nations to geopolitical conflicts and underscores the urgent need for diversified energy sources and more resilient supply chains in the region.

A Widow's Journey Through Grief I am alive. My husband, Paul Auster, is dead. He died on 30 April 2024, at 6.58pm here in the Brooklyn house where I am now writing these words. He was diagnosed with non-small cell lung cancer in January 2023. But before that, in early November 2022, Paul had a CT scan in the emergency room at Mount Sinai West hospital. The radiologist spotted a mass in his right lung and noted it might be cancer. We all die, but only some of us know our lives could end soon. Although I had often thought about what it would mean to live without Paul, I began to imagine it more often. I imagined walking around the house alone. I imagined grieving. If your father dies, I said to our daughter, Sophie, I will lose my every day. The Final Days with Paul Auster What I didn't imagine is that after Paul's death, time would be deranged beyond recognition. I remember and then forget what day it is. I remember it's the month of May and then forget. The hours skip ahead but minutes often move slowly. I want to root my body in calendar and clock, those reliable, if ultimately fictional, markers of time, but I'm not making sense of their regular beats. I'm afraid if I don't keep checking date, day and hour, I will lose my orientation, stumble on the stairs, and fall or float away ungrounded. In the days that immediately followed Paul's small graveside funeral, on 3 May at Green-Wood Cemetery, a compulsion to sort, throw and scrub came over me. When I'm distressed or anxious, I often clean. I get my own little world into shiny order. I exercise some control by getting rid of dust and fluff and blur. I was not going to be one of those widows who leaves her husband's clothes in the closet for months or even years. A dead man doesn't need shirts, keys, shaving cream. A dead man can't be sick. He doesn't take pills. The Physical Toll of Loss I have trouble breathing. My heart beats too fast, not all the time, in bursts. I have pains between my ribs, sometimes intense. My neck and head ache. My nerves buzz and hum, and electricity shoots up and down my limbs. I sleep by pill. I pick up a paper or an object that needs attention and then see another that calls to me. I put down the first thing only to spot it hours later, an inanimate victim of the unfinished gesture. A pile of unopened condolence letters and cards lie on the red table in the dining room. I cannot bear to open them. Not today. I will wait. Tomorrow. The Empty Spaces of a Shared Life The four-storey house in Brooklyn where Paul and I lived for 30 years and where our daughter, Sophie, grew up, and where Daniel, my stepson, lived when he wasn't at his mother's, became vast overnight. The two of us occupied this space for a long time without children, and the house felt roomy but not huge. I'm amazed by the determination with which I attacked Paul's study. He spent most of his days from morning into the afternoon writing in a small room at the back of our house near the garden. My guess is that there were at least 150 pens on the surface of Paul's desk. He had a supply of typewriter ribbons for his manual Olympia to last him several additional long lifetimes. He had a number of well-used erasers and 35 Clairefontaine notebooks, the kind with graph paper inside them. Paul's courage as he looked into the abyss astounded me. The man couldn't stand up from his bed alone. Finding Meaning in the Aftermath I have been sleeping on my side of the bed. So far, I haven't found myself taking up more room than I used to. When I wake, I do not expect him to be beside me. I do not expect him to walk into the room. I know I cannot conjure him, as much as I would like to. I dreaded his imminent death for far too long. I occupy the same space in the bed where we coupled and slept, year after year. We slept together in that bed for the last time on 28 April, two nights before he died. Spencer wheeled Paul into the room and helped me lift him on to the bed. He, Sophie and Miles had come to stay with us. After I crawled in with Paul, he stroked my hand and arm for what seemed like a long time. We talked. He wanted me to live on, live long, to write more. I woke up several times that night and reached out for him to make sure he was breathing. Paul loved the library on the third floor of the house. "I want to die in the library. I imagine putting a hospital bed in here," he said to me long before the hospital bed arrived and well before we knew the cancer had returned. He knew he wanted to die in that room filled with light. Light became more and more important to him as he neared death.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”